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Pheromone receptorsG protein coupled receptors are responsible for awide variety of signaling responses in diverse cell types. Despite
major advances in the determination of structures of this class of receptors, the underlyingmechanisms bywhich
binding of different types of ligands speciﬁcally elicits particular signaling responses remain unclear. The use of
ﬂuorescence spectroscopy can provide important information about the process of ligand binding and ligand de-
pendent conformational changes in receptors, especially kinetic aspects of these processes that can be difﬁcult to
extract from X-ray structures. We present an overview of the extensive array of ﬂuorescent ligands that have
been used in studies of G protein coupled receptors and describe spectroscopic approaches for assaying binding
and probing the environment of receptor-bound ligands with particular attention to examples involving yeast
pheromone receptors. In addition, we discuss the use of ﬂuorescence spectroscopy for detecting and character-
izing conformational changes in receptors induced by the binding of ligands. Such studies have provided strong
evidence for diversity of receptor conformations elicited by different ligands, consistent with the idea that GPCRs
are not simple on and off switches. This diversity of states constitutes an underlying mechanistic basis for biased
agonism, the observation that different stimuli can produce different responses from a single receptor. It is likely
that continued technical advances will allow ﬂuorescence spectroscopy to play an important role in continued
probing of structural transitions in G protein coupled receptors. This article is part of a Special Issue entitled:
Structural and biophysical characterisation of membrane protein–ligand binding.
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ights reserved.1. Introduction
Transmembrane receptors play critical roles in diverse cell signaling
pathways that affect many aspects of cell behavior. Their functions in
important physiological processes make them the targets of a large
16 R. Sridharan et al. / Biochimica et Biophysica Acta 1838 (2014) 15–33fraction of clinically useful drugs and candidate targets for the develop-
ment of many new drugs [1]. Activation or modulation of downstream
signaling pathways by receptors is generally initiated and controlled
by interactions of the receptors with different classes of chemical li-
gands. These include agonists, which lead to activation of downstream
pathways, antagonists, which do not activate the downstream path-
ways, but can inhibit activation by agonists, and inverse agonists,
which act directly to inhibit receptor-mediated activation of pathways.
Despite the importance of receptor–ligand interactions in controlling
cell signaling pathways, the mechanisms by which such interactions
elicit downstream responses remain poorly understood.
A major obstacle to understanding the molecular basis underlying
receptor–ligand interactions has been the lack of structural information
about receptors.Many receptors are transmembrane proteins for which
structure determination byX-ray crystallography andNMR is extremely
difﬁcult. However, over the past few years, major advances have been
made in determining structures of one particularly important class of
receptors, the G Protein Coupled Receptors (GPCRs). These constitute
a widely-distributed protein superfamily that is responsible for signal-
ing responses to awide variety of hormones, neurotransmitters, sensory
stimuli, metabolites, and ions. GPCRs all consist of membrane proteins
with seven transmembrane segments, an N-terminal extracellular por-
tion that can vary considerably in size, and a C-terminal cytoplasmic tail,
often involved in downregulation of signaling. Activation of GPCRs gen-
erally results in exchange of GTP for GDP bound to the α-subunit of a
heterotrimeric G protein, followed by at least partial dissociation of
the G protein α-subunit from the β- and γ-subunits. In some cases,
activation of GPCRs may also result in signaling via mechanisms
that do not involve G proteins, such as through interactions with
arrestins [2,3].
To date, structures are available for rhodopsin [4,5] and the β2-
adrenergic [6,7], A2a adenosine [8], dopamine D3 [9]; CXCR4 chemokine
[10], histamine H1 [11], lyso-phospholipid S1P [12], M2 and M3 musca-
rinic acetylcholine [13,14], δ-, κ-, and μ-opioid [15–17], neurotensin [18],
protease activated [19], serotonin [20], smoothened [21], glucagon [20],
and corticotrophin releasing factor [22] receptors. With the exception of
rhodopsin, all these structures have been obtained by fusing receptors
to stable soluble proteins, or by introducing a variety of stabilizing muta-
tions into the protein to render them stable enough to adopt a single state
for crystallization. Such modiﬁcations can have signiﬁcant effects on
the functions of receptors [23,24]. However, availability of these
structures provides critical information on GPCRs' overall topology,
on the nature of their ligand binding sites, and, in some cases, on
the nature of the conformational changes associated with receptor
activation [25].
Despite the recent structural characterization of GPCRs, the speciﬁc li-
gand–receptor interactions that drive conformational changes of GPCRs
that, in turn, result in activation or inhibition of receptor-mediated signal-
ing pathways, are not yet deﬁned. The diverse family of GPCRs apparently
share commonmechanisms for activating G proteins (for example, many
different receptors can activate the same G proteins), but the molecular
nature of the ligands that activate GPCRs is astonishingly diverse, ranging
from large glycoproteins that interact with large extracellular domains of
receptors to small molecules and ions, some of which appear to interact
directly with transmembrane regions of the receptors. Classical models
of receptor signaling postulated the existence of an active state of a recep-
tor that is stabilized by binding of agonists and an inactive state stabilized
by binding of inverse agonists. In this paradigm, ligands that act as antag-
onists bindwith equal afﬁnity to both active and inactive states, providing
competition that inhibits activation by agonists, but resulting in no activa-
tion of receptors by antagonists added by themselves [26,27]. However,
GPCRs appear to be more than simple two-state switches. A particularly
intriguing aspect of GPCR signaling is the accumulating evidence for bi-
ased agonism, in which different ligands binding to similar sites on a par-
ticular receptor are capable of eliciting different downstream signaling
responses [28].Fluorescence-based techniques provide diverse ways of probing the
chemical environments and intermolecular interactions that have been
extensively applied to understanding receptor-mediated signaling. We
focus in this review on applications in which these capabilities are
used speciﬁcally to probe receptor–ligand interactions and associated
conformational changes in GPCRs. Fluorescence has also been extensively
used for other types of studies of GPCRs that will not be discussed here,
including: 1) cell biological approaches inwhichﬂuorescencemicroscopy
is used to characterize the subcellular locations of GPCRs under resting
conditions and following stimulation; 2) examination of the dynamic na-
ture of interactions between GPCRs and their cognate G proteins [29–32];
and 3) characterization of the oligomeric state of GPCRs, a complex and
controversial topic that is beyond the scope of the present manuscript
but has been reviewed in several contexts [29,33–39].
This reviewwill also emphasize the usefulness of ﬂuorescent ligands
for studying GPCR signaling in the yeast pheromone response pathway.
This signaling system has served as the basis for uncovering several as-
pects of GPCR signaling that have proved to be broadly relevant to such
pathways inmammalian and other systems [40–42]. Haploid cells of the
bakers' yeast Saccharomyces cerevisiae secrete the mating type-speciﬁc
peptide pheromones a-factor and α-factor that bind to receptors on
cells of the oppositemating type, reporting that a potentialmating part-
ner is nearby. Such signaling results in morphological changes, tran-
scriptional reprogramming, and cell cycle arrest that prepare the
haploid cell for mating to form a diploid zygote. The receptors for
yeast mating pheromones are GPCRs that are, in some cases, functional-
ly interchangeable with mammalian receptors, despite exhibiting very
little sequence similarity to their mammalian counterparts [43–46]. In
contrast, the sequences of trimeric G proteins in yeast are very similar
to those of mammalian G proteins. The genetic approaches possible in
yeast, along with the development of robust and diverse readouts for
pheromone receptor activation, have resulted in a high level of charac-
terization of this signaling system that has been complemented by the
application of quantitative systems-based approaches for detailed anal-
yses of pheromone signaling responses [47–49].
2. Fluorescent ligands
The usefulness of ﬂuorescently labeled ligands for the study of
GPCRs has been recognized for several decades [50–54]. Fluorescent
GPCR ligands have been used for studies ranging from localization of re-
ceptors in tissues and cells (including an early demonstration of the in-
ternalization of ligand-bound receptors in cells [53]), to simple binding
assays (in many cases, as replacements for radioligands), to sophisticat-
ed probing of the geometry andmechanisms of ligand–receptor interac-
tions and receptor–receptor interactions. Several previous reviews have
provided compendia of ﬂuorescent ligands for GPCRs that have been
reported in the literature [29,55–61]. Table 1 presents an updated list
of published ﬂuorescent ligands for GPCRs, including information from
these previous reviews.
Since most GPCR ligands are not inherently ﬂuorescent, the use of
ﬂuorescent ligands to study GPCRs requires modiﬁcation of normal
ligands to render them ﬂuorescent. A signiﬁcant problem in the ﬁeld
is the fact that such modiﬁcations can alter the ligands' properties, in-
cluding, importantly, the nature of their interactions with receptors. Al-
teration of ligand properties is obviously a major issue in creating
ﬂuorescent derivatives of small molecule ligands, such as biogenic
amines (see [59]), where the native ligands are smaller than any ﬂuo-
rescentmoiety towhich they can be conjugated.However, the introduc-
tion of a ﬂuorophore can also lead tomajor alterations of the properties
of larger ligands, such as peptides [57]. For example, upon testing of ﬁf-
teen different analogs the yeast peptidemating pheromone,α-factor in
which the small NBD (7-nitrobenz-2-oxa-1,3-diazol-4-yl) ﬂuorophore
was attached at 7 out of 13 possible amino acids in the peptide, each
of the analogs exhibited at least moderately reduced binding afﬁnity
for receptor, and several of the analogs had binding afﬁnities that
Table 1
G protein coupled receptors that have been studied using ﬂuorescent ligands.
Class of receptor References
α-Adrenergic [204–208]
β-Adrenergic [50–52,65,71,87,88,206,209–219]
Adenosine [69,85,86,220–235]
Angiotensin [236,237]
Apelin [238]
Bradykinin [239]
Cannabinoid [89,163,240–242]
Chemokine [72,76,90,91,243–246]
Cholecystokinin/gastrin [112–114,133,134,247–250]
Dopamine [251]
Endothelin [68,73,252,253]
Free fatty acid (GPR40) [93]
Formyl peptide [254–262]
Galanin [92,263]
Glucagon [67,264,265]
Ghrelin (growth hormone secretagogue) [117,266]
Histamine [267–276]
Leukotriene [277]
Melanocortin [278,279]
Muscarinic acetylcholine [78,104–107,194,280–282]
Neuropeptide Y [94,283–289]
Neurotensin [290,291]
Opioid [206,290,292–307]
Oxytocin/vasopressin [98,111,118,308–312]
Parathyroid hormone [108,313]
Relaxin [314]
Secretin [115,135]
Serotonin [315–318]
Somatostatin [95,96,290,319–324]
Tachykinin [109,110,116,131,132,289,325–328]
Thyrotropin releasing hormone [329]
Urotensin [97]
Vasoactive intestinal peptide [95,289]
Yeast α-mating pheromone [62–64,82,99,101,172,330–332]
17R. Sridharan et al. / Biochimica et Biophysica Acta 1838 (2014) 15–33were reduced to undetectable levels [62]. Thus, it is important to note
that the diverse ligands included in Table 1 have been characterized to
different extents, using a wide variety of different assays. These range
from simplemicroscopic evaluation of patterns of ﬂuorescence localiza-
tion on cells to full pharmacological characterization of binding and sig-
naling efﬁcacy and potency. In many cases, the actual binding afﬁnities
of the modiﬁed ligands and their tendencies to bind non-speciﬁcally to
receptor preparations are not well characterized. Some ﬂuorescent li-
gands are commercially available from sources such as Abcam Plc.,
Cell Aura Technologies Ltd., Life Technologies Corp., and Sigma Aldrich
Co. However, it is important to note that not all commercially available
products have been pharmacologically well-characterized.
2.1. Binding assays using ﬂuorescent ligands
Initial characterization of many ﬂuorescent ligands has been
conducted via competition assays against previously-characterized
radiolabeled ligands (in the case of binding assays) and unlabeled li-
gands (in the case of assays of signaling responses). However, we
focus here on assays of ligand binding that speciﬁcally make use of the
ﬂuorescent properties of ligands (see Fig. 1). As in any binding assay,
some of the factors that must be considered relating to ﬂuorescence-
based binding assays include the ability to distinguish bound from
unbound ligand, the ability to distinguish speciﬁc from non-speciﬁc
binding (or between different classes of binding sites present in the
same preparation of receptors), and the ability to distinguish actual re-
versible binding from internalization of ligand into cells. One aspect of
ﬂuorescence-based binding assays that requires additional consider-
ation, compared to radioligand binding assays is the difﬁculty of quanti-
tating the total concentration of binding sites in a preparation in
absolute terms. In ﬂuorescent assays, curve ﬁtting of the data only yields
an estimate of relative ﬂuorescence levels at saturation, but no absolute
determination of the actual concentrations of receptors, in contrast toradioligand binding assays with tracer of known speciﬁc activity. The
actualﬂuorescence levelsmeasured in a binding experiment are strong-
ly affected by the sensitivity and geometry of the detecting instrument.
Even if calibrated against a known quantity of a known ﬂuorophore,
such as ﬂuorescein, the material used for calibrating must be present
in a similar light-emitting geometry to that of the bound ligand, which
can be difﬁcult, especially when using ﬂow cytometry. Such a calibra-
tion against a standard ﬂuorophore also depends critically on the as-
sumption that the ﬂuorescent properties of the ﬂuorophore used for
the binding assay are the same as the standard. This is frequently not
the case, since the quantum yield and absorbance of a ﬂuorophore will
generally be affected by the details of its chemical environment, such
as the mode of conjugation to the ligand and the chemical properties
of a receptor's ligand binding site.
Another signiﬁcant issue in experiments involving ligand binding to
whole cells is the problemof distinguishing initial binding to cell surface
receptors from effects due to internalization of ligand-bound receptors,
which can result in irreversibility of the binding reaction and environ-
mental changes that can affect ﬂuorescence of bound ligand. Internali-
zation can often be prevented by conducting binding experiments at
low temperatures or in the presence of metabolic inhibitors, however,
this may not completely block endocytosis and may not block initial re-
cruitment to the endocytotic apparatus in cells. Problems associated
with receptor internalization generally impose a limit on the length of
time over which binding and dissociation experiments can be performed.
Approaches used for assaying the binding of ﬂuorescently-tagged
ligands to receptors include:
1) Evaluation of staining patterns by ﬂuorescence microscopy. This is
an approach that has been applied for many of the ligands listed in
Table 1, dating back to the ﬁrst uses of ﬂuorescent GPCR ligands
[50–53]. It provides useful information about localization in tissues
or at the subcellular level, but is of little value for providing insight
into themechanisms of ligand binding or receptor activation. Deter-
mining accurate binding afﬁnities by this approach is challenging,
since it may be difﬁcult to accurately quantitate cell associated ﬂuo-
rescence and to correct for the contributions from cellular autoﬂuo-
rescence and non-speciﬁc binding, and since these measurements
can be confounded by signiﬁcant cell-to-cell variation.
2) Evaluation of bulk binding by separating bound from free ligand.
Fluorescent ligands can be used as replacements for radioligands in
saturation or competitive ligand binding analyses in which physical
means, such as ﬁltration, or centrifugation (for cells or membranes)
or afﬁnity or size exclusion chromatography (for puriﬁed receptors)
are used to separate free from bound ligand. However, quantitation
of ﬂuorescent ligands in different fractions may be complicated by
the presence of autoﬂuorescent material in receptor preparations,
by lower sensitivity of ﬂuorescence detection compared to some
radioligands, by differences in ligand ﬂuorescence emission as a
function of environment (such as in comparing bound and free li-
gand), andby theﬁnite off-rate of some ligands,which can allowdis-
sociation during washing steps. As an example, physical separation
of free from Ste2p receptor-bound pools of a ﬂuorescent analog of
yeast α-factor was reported using afﬁnity chromatography [63]. In
some cases, free and bound ligand can be distinguished under equi-
librium conditions via equilibriumdialysis, an approach that has also
been applied in the yeast pheromone response system [63].
3) Determination of changes inﬂuorescence emission spectrumor inten-
sity of a bulk solution containing receptors and ligand. In cases where
the emissionof aﬂuorescent ligand changes uponbinding to receptors
binding can bemeasured using a conventional cuvette-based ﬂuorim-
eter or a ﬂuorescent plate reader (including real-time PCR instru-
ments) in a bulk solution containing receptor without the need to
separate bound from free ligand. This approach relies on the ability
to distinguish speciﬁc binding-dependent ﬂuorescence changes from
ﬂuorescent background contributions arising from unbound ligand,
AB
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ceptor is present in cells or membranes, these need to be maintained
in a homogeneous suspension. The approach is not widely used, but
has been applied to the binding of α-factor to yeast membranes
[62,64] based on an observed large increase in ﬂuorescence on bind-
ing. Small changes in emission spectrum of the ﬂuorescent antagonist
carazolol have been reported upon binding to puriﬁed β-adrenergic
receptors [65], decreases in ﬂuorescence emission have been reported
upon binding of ﬂuorescent derivatives of substance P to membranes
containing the neurokinin 1 receptor [66], and an increase in ﬂuores-
cence intensity has been detected in the binding of a ﬂuorescent glu-
cagon analog to its receptor [67]. An interesting variation of this
approach is the spectroﬂuorimetric determination of the binding of a
ﬂuoresceinated N-formyl peptide to its cognate receptor using anti-
ﬂuorescein antibodies to selectively quench the ﬂuorescence of
unbound ligand [54]. A convenient approach for this type of measure-
ment is to monitor changes in the emission from a constant concen-
tration of ﬂuorescent ligand upon adding increasing concentrations
of a receptor-containing preparation. In general, such studies are
conducted using ﬂuorescent ligand concentrations that are near or
below the dissociation constant for binding, so as to provide the
greatest change in overall ﬂuorescence per increment of binding.
4) Detection of changes in ligand mobility via Fluorescence Correlation
Spectroscopy (FCS). FCS, the measurement of time-dependent ﬂuc-
tuations in ﬂuorescence emission from a small illuminated volume
provides a way of measuring the diffusion of ﬂuorescently labeled
molecules in solution. This can be used to distinguish between li-
gands that are freely diffusing in solution from those that diffuse
more slowly by virtue of being bound to membranes, cells or large
particles [60]. Thus, the ability of FCS to provide simultaneous track-
ing of free and bound populations in the same solution provides a
basis for measuring binding in a time-dependent manner under
equilibrium conditions, with no need to physically separate bound
fromunbound ligand.However, one complication is thatmultiple spe-
cies of ligandwith different characteristic diffusion times are often de-
tected for a given ligand bound to a particular type of receptor [60].
This may reﬂect different states of homomeric or heteromeric pro-
tein–protein association or different subcellular localizations of the
particular receptor being studied. Thus, FCS has beenused in anumber
of instances to measure the mobilities of receptors and to provide an
estimate of their oligomeric states. It has also been used as an assay
for binding of ﬂuorescent ligands to the endothelin [68], adenosine
A1 [69], melanin concentrating hormone, gastrin releasing peptide,
and β-adrenergic receptors [70,71].
5) Detection of changes in ﬂuorescence anisotropy upon binding. The
fact that lowmolecular weight ligands undergo rapid rotational mo-
tion in solution, but are more restricted when bound to large recep-
tors, provides the basis for measuring ligand binding using steady
state ﬂuorescence anisotropy or polarization.Molecules that are illu-
minatedwith linearly-polarized light will emit with a deﬁned polar-
ization with respect to the incident beam if rigidly held in place, butFig. 1. Schematic representations of ligand-binding assays using ﬂuorescent ligands. In each cas
the receptor is represented as purple hepta-helical bundle. A) Determination of ligand binding
ligand in separate fractions are determined through measurement of total ﬂuorescence emiss
ﬂuorescence emission spectrum or intensity of a bulk solution containing receptors and ligand
are quantitated as a function of increasing ligandor receptor concentration. C)Determination of
Spectroscopy (FCS). Rapid ﬂuctuations in ﬂuorescence emission of ligand in a small illuminated
plished by distinguishing the population of rapidly diffusing free ligand from that of slower diffu
time (related to τ, the time scale of the observed ﬂuctuations) and an estimate of the fraction
based on changes in ﬂuorescence anisotropy upon binding. When free ligand undergoing rapid
is depolarized because the emitting dipole rotates during the time interval between ﬂuorescence
to ﬂuorescence emission that maintains linear polarization. The extent of polarization of a soluti
and bound populations of ligand. E) Determination of ligandbinding usingﬂow cytometry. Illum
determination of the amount of bound ﬂuorescent ligand. Data is presented as a histogram sh
Often a control sample containing cells or beads without receptors or a sample incubated w
used as a control for autoﬂuorescence and non-speciﬁc binding. F) Determination of ﬂuoresce
receptor. Binding of ligand to receptor leads to transfer of ﬂuorescence from donor to acceptor
Although the illustration shows the donor conjugated to ligand and the acceptor conjugated tothe orientation of the polarization will be randomized if the mole-
cule rotates signiﬁcantly during the time span of the excited state
of the ﬂuorescent transition. Binding assays based on ﬂuorescence
polarization have been used to characterize the ligand binding prop-
erties of puriﬁed receptors, including chemokine and endothelin
receptors [72,73], and are particularly well-suited for use in high-
throughput screening [70,74–78]. As with other spectroscopic
assays, anisotropy-based binding can be measured in equilibrium
experiments, with no need to separate bound from unbound ligand.
Measurements can be made using a ﬂuorimeter or a ﬂuorescence
plate reader with polarization capabilities. One limitation of such
studies stems from the fact that measured steady-state anisotropy
of a bulk solution provides only a single number that is averaged
over the anisotropies of different species present in the solution,
weighted by their ﬂuorescence emission intensities. Thus, in order
to signiﬁcantly change the anisotropy of the population of ligand
molecules, a signiﬁcant proportion of the ligand in solutionmust be-
come bound to receptor. Meeting this condition requires the pres-
ence of a concentration of binding sites that is of the same order as
the concentration of ligand, and whichmust, in a typical binding ex-
periment, also be of the same order as the dissociation constant of
the interaction [79]. The use of such high concentrations of binding
sites may be difﬁcult to achieve for some receptor preparations,
and may lead to high backgrounds if the receptor preparation is
associated with signiﬁcant autoﬂuorescence. To circumvent some of
these problems, ﬂuorescence polarization assays are often performed
as competitions, under conditionswhere the ﬂuorescent ligand is pre-
dominantly bound to receptors until displaced by unlabeled ligand.
Binding experiments are also often performed as titrations of increas-
ing amounts of receptor preparation into a constant concentration of
ﬂuorescent ligand. Polarization changes of the ﬂuorescent ligand
carazolol upon binding toβ-adrenergic receptors have also beenmon-
itored by chromatographic separation of free ligand receptor–ligand
complexes [65].
6) Flow cytometry. Sklar and coworkers originally demonstrated that
ﬂow cytometry can provide unique advantages for assays of ligand
binding to receptors (see [54,80,81]). Flow cytometersmeasureﬂuo-
rescence onlywhen a cell (or other particle) passes through the nar-
rowﬂuid path of a ﬂow cytometer, collecting emitted light only from
a small volume surrounding the particle. This allows determination
of the amount of ﬂuorescent ligand associated with cells in a homo-
geneous suspension with no need to physically separate free from
bound ligand. The approach can be used even when binding of ﬂuo-
rescent ligand to receptors does not result in any change in ﬂuores-
cence emission. However, its sensitivity is enhanced in cases where
ﬂuorescence of the bound ligand increases or alters in wavelength
upon binding, as observed for binding of ﬂuorescent derivatives of
yeast α-factor to the α-factor receptor [82]. The fact that ﬂow
cytometry can detect binding under equilibrium conditions raises
the possibility of examining relatively low afﬁnity interactions for
which problems of ligand dissociation could be severe in assayse, the ﬂuorescent ligand is indicated by a red oval with an attached green ﬂuorophore and
using physical separation of bound and free ligand. The concentrations of free and bound
ion intensities in each fraction. B) Determination of ligand binding based on changes in
. Relative changes in ﬂuorescence intensity or wavelength reﬂecting binding to receptors
ligandbinding throughdetection of changes in ligandmobility via Fluorescence Correlation
volume reﬂect the diffusion time of the labeled entity. Quantitation of binding is accom-
sing bound ligand. Analysis of the ﬂuctuations in emission allows assignment of a diffusion
of the population associated with each diffusion time. D) Determination of ligand binding
rotational diffusion is illuminated with linearly polarized light, the emitted ﬂuorescence
excitation and emission. Receptor-bound ligandundergoesmuch slower rotation, leading
on of ﬂuorescent ligand and receptors is a weighted average of the emissions from the free
ination of a small volume containing receptors expressed on cells or bound to beads allows
owing the percentage of cells or beads exhibiting a given ﬂuorescence emission intensity.
ith ﬂuorescent ligand in the presence of a large excess of non-ﬂuorescent competitor is
nt ligand binding based on FRET between a ﬂuorescent ligand and a ﬂuorescently labeled
that can be detected via a decrease in donor emission or an increase in acceptor emission.
receptor, the opposite conﬁguration is also used.
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However, a practical lower limit on the afﬁnities of interactions
that can be studied in this way arises from the ﬂuorescence of high
concentrations of unbound ligand in the illuminated volume of the
ﬂow cytometer whenworking at high ligand concentrations needed
to study weak binding. On the other hand, assays can be conducted
at very low cell densities, resulting in a low overall concentration
of receptors, as needed for assaying interactions with low dissocia-
tion constants without complications introduced by ligand deple-
tion. Ligand binding can be quantitated in either saturation- or
competition-type assays. A practical lower limit of detection of
about 1000 ﬂuorescein molecules per cell or particle arises from dif-
ﬁculty of distinguishing the ligand emission from the background of
autoﬂuorescence of the cells or particles (see [80]). This limit is usu-
ally well above any limitations from the ﬂuorescence detection sen-
sitivity of current instruments. The capability to time-stamp data
from each cell passing through the cytometer makes it possible to
follow the kinetics of ligand–receptor interactions. The variety of ex-
citation lasers and detection channels available on modern ﬂow
cytometers allows the use of a wide range of ﬂuorophores, either
singly or in multiplexed conﬁgurations. Although ﬂow cytometry-
based assays of ligand binding are generally performed with cells,
the beneﬁts of the approach have been realized in assays of binding
of components to puriﬁed receptors attached to synthetic beads, in-
cluding a reconstitution of ligand interactions with formyl peptide
receptors [83] and β2-adrenergic receptors with trimeric G proteins
[84] on the surface of beads.
Many of the early studies establishing ﬂow cytometry as a ligand
binding assay were performed with formyl peptides serving as li-
gands for chemotactic receptors. However, the approach has also
been used for ligands for adenosine [85,86], adrenergic [87,88], can-
nabinoid [89], chemokine [90,91], galanin [92], long chain fatty acid
[93], neuropeptide Y [94], somatostatin [95,96], urotensin [97], vaso-
pressin [98] and yeast α-factor [82,99–102] receptors.
7) Ligand–Receptor Fluorescence Resonance Energy Transfer. The bind-
ing of a ﬂuorescent or dye-labeled ligand to a receptor can be moni-
tored via Fluorescence Resonance Energy Transfer (FRET) between
the ligand and a ﬂuorescent group attached to the receptor. FRET is
the non-radiative transfer of energy between two ﬂuorophores or
chromophores where the emission from one overlaps the excitation
of the other. The strong (1/r6) distance dependence of the interaction
makes it useful for measuring distances or determining whether the
labels are in close proximity on the scale of 1–10 nm. The presence
of FRET can be detected either via enhanced emission of the longer
wavelength (acceptor) ﬂuorophore, or via loss of emission from the
shorter wavelength (donor), even if the acceptor is not ﬂuorescent.
Inmany cases, binding can bemeasured based on FRET changeswith-
out any requirement to separate bound from unbound ligand,
allowing determination of binding kinetics on a rapid time scale. If
ﬂuorescent backgrounds are low and there is minimal bleedthrough
of donor emission into the acceptor channel and minimal direct exci-
tation of the acceptor by donor excitation, FRET-based approaches can
be sufﬁciently sensitive to detect relatively low occupancies of ligand
bound to receptors.
Labeling of GPCRs for this type of assay can be accomplished by fusing
ﬂuorescent proteins to the extracellular N-terminal region of the
receptors, by speciﬁcally attaching small ﬂuorescent tags to the N-
terminal of the receptor, or through binding of a ﬂuorescently labeled
antibody to the native N-terminal of a receptor or an epitope fused at
this position. In some cases, FRET can be measured in a time-resolved
mode, using a lanthanide-containing donor with a long-lived excited
state and a large Stokes shift (between excitation and emission) to re-
move background contributions from autoﬂuorescence, direct excita-
tion of acceptor, and bleedthrough of donor emission (see [103]). It is
also sometimes possible to detect binding in circumstance where one
member of a FRET pair (either donor or acceptor) is speciﬁcallylabeled and the other member is not, since the FRET-dependent
change in the speciﬁc label should only occur when it interacts with
the non-speciﬁcally labeled partner. This, for example, raises the pos-
sibility of measuring binding of a speciﬁcally ﬂuorescently labeled li-
gand to a cell in which surface proteins have been non-speciﬁcally
labeled with a ﬂuorophore that can serve as a FRET partner to the li-
gand.
FRET between labeled ligands andGPCRs fused toﬂuorescent proteins
has been used to detect ligand binding M1 muscarinic acetylcholine
receptors [104–107], parathyroid hormone receptors [108], and
neurokinin NK2 receptors [109,110]. FRET between labeled ligand
and ﬂuorescent antibody bound to vasopressin receptors has also
been reported [111]. FRET with ﬂuorescent ligands has also been
used in combination with small ﬂuorophores covalently attached to
introduced cysteine residues in cholecystokinin (CCK) receptors
[112–114] and secretin receptors [115] and via biosynthetic incorpo-
ration of unnatural amino acids into the neurokinin-2 receptor [116].
Several studies have also taken advantage of recently-developed
enzyme-based approaches for tagging receptors with small molecule
ﬂuorophores for ligand–receptor FRET studies. These include studies
of ligand binding to ghrelin receptors [117], V2 vasopressin receptors
[118], and numerous additional types of receptors [119].
2.2. Stabilization of GPCRs for structure determination based on preservation
of ﬂuorescent ligand binding by mutant receptors
Recent crystal structures of GPCRs have highlighted the importance
of protein stability in the generation of protein crystals. The structures of
the β1-adrenergic, the A2a adenosine, and neurotensin receptors were
solved using constructs that incorporated several stabilizing mutations
[18,120,121], while several others have been solved by replacing a
ﬂexible intracellular loop with T4 lysozyme or other stable soluble pro-
teins, which is thought to decrease the conformational ﬂexibility of the
protein while also providing extra surfaces for crystal contacts (see
[122]). Other GPCR structures have been solved using antibodies to sta-
bilize the protein [123–125]. Thus, amajor bottleneck in the determina-
tion of GPCR crystal structures appears to be the identiﬁcation of ways
to improve the stability of solubilized receptors. Recently, ﬂuorescent
GPCR ligands have been used in conjunction with Fluorescence Activat-
ed Cell Sorting (FACS) of cells expressing libraries of randomly mutated
receptors to screen for receptor mutations that improve the stability of
GPCRs.
One such directed evolution-based approach focusing on receptors
expressed in Escherichia coli led to the identiﬁcation of mutations in
the gene for the neurotensin receptor 1 that improved GPCR expression
~10-fold [126]. When tested for thermal stability, a high-expressing
mutant clone was also found to exhibit improved stability. In a more
comprehensive study the laboratory of Andreas Plückthun generated
libraries of mutants in which all 64 possible codons were substituted
at every codon position of the same neurotensin receptor [127,128].
FACS based on ﬂuorescent ligand bindingwas used to select for high ex-
pressing clones which were then subjected to high throughput se-
quencing to determine the frequency of each codon at each position.
By combining several of the mutations, a clone was identiﬁed that
improved expression even further compared to the clone identiﬁed in
the prior study. When similar mutagenic and ﬂuorescent screening
techniques were applied to three other GPCRs, the tachykinin receptor
NK1, the α1a-adrenergic receptor, and the α1b-adrenergic receptor,
clones with improved expression and thermal stability were identiﬁed
for each receptor, indicating that the procedure can be generally applied
to proteins for which ﬂuorescent ligands are available [129].
A similar approach has recently been applied for the identiﬁcation
of stabilizing mutations from randomly mutagenized libraries of yeast
α-factor receptors expressed in yeast cells (Zuber and Dumont,
unpublished results). Binding of NBD-labeled α-factor was also used to
identify α-factor receptors retaining ligand binding activity from a
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tions in the vicinity of the third intracellular loop. A further selection for
T4 lysozyme-containing receptors that retain signaling function was
also conducted, allowing recovery of lysozyme-inserted variants that
retain full ability to bind ligand and activate the pheromone response
pathway [102]. Flow cytometric measurements of binding of a ﬂuores-
cent alprenolol derivative have also been used in evaluation of the
ligand-binding capabilities of potentially stabilizing site-directed muta-
tions in the β2-adrenergic receptor [88].
Some of the attempts to achieve mutagenic stabilization of GPCRs
assayed by ﬂuorescent ligand binding have been based on the assump-
tion that therewill be a correlation between receptor expression in cells
and receptor stability in detergent. In these studies, receptors were ﬁrst
optimized through directed evolution for expression in a cell system,
and then tested individually for improved stability in the solubilized
state. A new approach by Scott and Plückthun, in contrast, directly
screens for protein stability in detergent using a technique referred to
as CHESS (Cellular High-throughput Encapsulation, Solubilization, and
Screening) [130]. Prior to receptor solubilization, bacterial cells are en-
capsulated within a polymer coating that is impermeant to large mole-
cules, while allowing small molecules such as ﬂuorescent ligands and
detergents to pass through. This conﬁnes solubilized receptors within
amatrix that canbe sortedusingﬂowcytometrywhilemaintaining an as-
sociation between eachmutated receptor and its genetic coding informa-
tion, as is required to identify the relevant mutations in the stabilized
variants. This method has been used to identify stabilizing mutations in
neurotensin and α1a-adrenergic receptors.
2.3. Use of ﬂuorescent ligands to probe the geometry and environment of
GPCR ligand binding sites
2.3.1. FRET-based mapping of ligand binding sites
The strong dependence of FRET efﬁciency on the spatial separation
between donor and acceptor has served as a basis for using ligand–
receptor FRET to map the distances between different labeled groups
on ﬂuorophores and labeled groups on receptors. Such measurements
can be much more precise when the FRET is measured between small
ﬂuorophores thanwhen the donor or acceptor is a large ﬂuorescent pro-
tein, where the actual location of the absorbing and emitting dipoles
may be poorly deﬁned and close apposition of donor and acceptor is
hindered by steric constraints. A model of the interactions of CCK pep-
tides with CCK receptors has been derived from triangulation of dis-
tances determined by FRET between small ﬂuorophores attached at
different positions to peptide ligands and smallﬂuorophores speciﬁcally
attached to receptors in tissue culture cells at cysteine residues intro-
duced by site-directed mutagenesis [112,114]. Although many proteins
at the cell surface are labeled with acceptor dye by this approach, the
speciﬁcity of the observed FRET signal is provided by the binding
speciﬁcity of the labeled ligands. The same group also took a similar ap-
proach for modeling the geometry of secretin binding to its receptor
[115].
2.3.2. Probing of ligand binding sites based on ﬂuorescent properties of
labeled ligands
In addition to providing an assay for whether or not ligand binds to a
particular GPCR, the use of ﬂuorescent ligands makes it possible to
probe the environment and geometry of the ligand binding site, as
well as kinetic aspects of ligand binding to receptors. For example,
some environmentally-sensitive ﬂuorophores change their quantum
yields or emission spectra in response to changes in their surroundings,
particularly the polarity of their immediate environment. Such changes
are readily observable upon examination of the ﬂuorescent properties
of the ﬂuorophore or the ﬂuorescently tagged ligand in the presence
of solventswith different polarities. A usefulmeasure of the accessibility
of bound ligand to aqueous solution is also provided by the degree of
quenching observed upon addition of quenchers such as iodide ions toa suspension or solution containing ligand–receptor complexes. In
such experiments, it is important to control for the effects of the chang-
ing ionic strength of the solution at different iodide concentrations [64].
Examples of GPCRs with ﬂuorescent ligands that have been used to
probe the environment of ligand binding site include: 1) the galanin re-
ceptor. Analysis of quenching was used to determine that the receptor-
bound ligand is sequestered in a hydrophobic binding site [92]; 2) the
neurokinin NK1 receptor. The bound state of a dansylated non-peptide
antagonist exhibited an increase in emission intensity, a blue-shift
of emission, and a reduced susceptibility to collisional quenching, com-
pared to the same ligand in the unbound state. No such ﬂuorescent
changes were seen for any dansyl groups attached to each of four differ-
ent positions on the NK1 peptide agonist substance P, underscoring the
existence of signiﬁcant differences in binding between peptide and
small molecule ligands [131]; 3) the neurokinin NK2 receptor. Varia-
tions in the length of the spacer arm connecting an environmentally
sensitive NBD ﬂuorophore to the N-termini of peptide antagonist li-
gands resulted in drastic changes in ﬂuorescence emission and in sus-
ceptibility to quenching. This led to the inference that the labeled
region of these antagonists is buried to a depth of only 5–10 Å in a hy-
drophobic binding pocket. On the other hand, similar ﬂuorophores at-
tached to N-termini of agonist peptide ligands did not show these
hallmarks of inaccessibility to solvent [132]. A ﬂuorescent non-peptide
antagonist exhibited even higher ﬂuorescence emission and anisotropy
than labels attached to the peptide antagonists, implying that it resides
in a site that is even more sequestered from solvent and restricted in
motion than peptide ligands [131]; and 4) β-adrenergic receptors. The
ﬂuorescent antagonist carazolol, when bound to receptors, exhibited
changes in emission spectrum and susceptibility to quenching on bind-
ing, indicative of residing in a hydrophobic binding site [65].
Detailed analyses of changes in ﬂuorescence emission, quenching,
anisotropy and lifetime on ligand binding to CCK and secretin receptors
have been conducted by Miller and co-workers. Binding of ﬂuorescent
ligands to preparations containing these receptors results in small
changes in emission intensity and small spectral shifts. In the case of
the CCK receptor, differences were observed between the binding-
associated ﬂuorescence changes of related agonist and antagonist
peptides that were similarly labeled at their amino termini. The differ-
ences were indicative of greater exposure of N-termini of agonist
ligands to aqueous solution than for similarly labeled antagonists. Treat-
ment of the receptor preparations with non-hydrolyzable GTP analogs
resulted in a shift in the ﬂuorescence of bound agonist toward a more
antagonist-like state [133]. Surprisingly, in comparisons of the related
type A and B CCK receptors, signiﬁcant differences were seen in the ap-
parent solvent accessibility of the bound state of the same ﬂuorescently
labeled peptide ligand, despite the fact that this peptide binds both re-
ceptor types with the same afﬁnity and exhibits similar potencies to-
ward activation of the two types [134]. In the case of the secretin
receptor, quenching of the ﬂuorescence of Alexa Fluor 488-labeled se-
cretin was enhanced by the presence of a non-hydrolyzable GTP analog
when the label was attached at two internal amino acids of the peptide
sequence, suggesting that these regions become more solvent-exposed
when the secretin receptor is in the active state. Corresponding changes
in anisotropy and ﬂuorescence lifetime were also observed for labels at
these two positions [135].
Fluorescent analogs of the yeast mating pheromone α-factor have
been extensively used to probe the environment of the ligand binding
site of the α-factor receptor Ste2p. Naider and co-workers found that,
in contrast to other positions on the 13-residue peptide ligand, Lys7,
could be modiﬁed by attachment of the small environmentally-
sensitive ﬂuorophore NBD with minimal effects on signaling responses
[62,64,82]. Binding of the Lys7 derivative, [K7(NBD),Nle12] α-factor, to
Ste2p results in blue-shifting of the ﬂuorescent emission, an increase
in the intensity of emission, and enhanced resistance to collisional
quenching by iodide, compared to the ﬂuorescent properties of this
same ligand in aqueous solution. These changes indicate that binding
Fig. 2. Predicted topology of a C-terminally truncated form of the α-factor receptor Ste2p indicating the positions of residues identiﬁed as affecting the ﬂuorescence emission of labeled
agonist and antagonist [100]. The residues indicated in red or purple are the sites of mutations that red-shift the emissionwavelength of receptor-bound agonist [K7(NBD),Nle12]α-factor.
These sites are postulated to interact directly with the ligand, rendering the environment of the ﬂuorophore more polar. The residues indicated in blue or purple are sites at which
mutations lead to blue-shifting of the receptor-bound antagonist [DTyr3,Lys7(NBD),Nle12]α-factor, indicative of transfer to a less polar environment.Mutations at these sites are postulated
to act indirectly on the ﬂuorescent ligand by shifting the overall receptor conformation to a state resembling that of the activated receptor, since they lead to constitutive signaling activity
and enhanced afﬁnity for antagonist without, in most cases, affecting the spectrum of bound agonist.
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side chain of this Lys7. However, this reduced accessibility does not re-
sult in deep burial of the Lys7 side chain, since changing the Lys spacer
arm by even a single carbon atom results in signiﬁcant alteration of
emission properties and susceptibility to quenching [64].
Our laboratory [100] used a genetic screen in conjunction with ﬂuo-
rescent ligand binding to identify the regions of the receptor that are dif-
ferentially involved in interactions with the normal agonist, α-factor,
and with a series of known peptide antagonists for this receptor
[136–138]. The results are summarized in Fig. 2. This approach was
based on the establishment of ﬂow cytometric methods for monitoring
ligand binding by Sklar and co-workers [58,80], and on the application
of ﬂow cytometry to genetic screening of large mutational libraries in
yeast developed primarily by Wittrup and co-workers [139,140]. It
was also based on the discovery of binding-dependent ﬂuorescence
changes in the intensity and wavelength of ﬂuorescence emission of
the ligand [K7(NBD),Nle12] α-factor and other related α-factor analogs
[62,64,100].
To identify residues in the receptor that are close enough to the NBD
ﬂuorophore of the bound ligand to affect its ﬂuorescence emission, we
conducted a screen for amino acid substitutions in receptors that alter
the emission spectrumof theNBDon bound ligand, while retaining nor-
mal receptor conformation, expression levels, and targeting to the plas-
ma membrane (based on ﬂuorescent ligand binding). This was
accomplished by creating a library of yeast cells expressing randomly
mutagenized STE2 genes encoding α-factor receptors, then usingﬂuorescence activated cell sorting of cells pre-incubated with NBD-
labeled ligand to collect cells that exhibit an altered emission spectrum,
based on detection of changes in the ratio of emission intensities in two
different wavelength channels of the cell sorter. By performing the cell
sorting in the presence of a relatively low concentration of ligand, and
sorting for cells that exhibit high overall levels of bound ﬂuorescence,
we were able to directly screen for cells expressing mutant receptors
that retain high afﬁnity for ligand (indicating that they retain a native-
like overall fold) and that are present at the cell surface at nearly normal
levels. A set of 18 amino acid substitutions in theα-factor receptor that
cause red-shifting of the bound ligand analog was identiﬁed. A spectral
shift in this direction is suggestive ofmutation-induced changes that in-
crease exposure of the labeled region ofα-factor to the aqueous solvent.
No substitutions causing blue-shifting were recovered. Despite the fact
that the mutagenized regions extended over all the predicted loops
and transmembrane segments of the receptor, the 18 mutations that
were recovered were all located in a region predicted by topological
models to reside at the interface between the transmembrane helices
and the external loops. Several of the identiﬁed mutations occurred at
residues that had already been implicated in ligand contact or recogni-
tion, however some mutations were also found at sites that had not
been previously implicated in interactions with ligand. None of the re-
covered mutations resulted in any signiﬁcant alteration of the ﬂuores-
cence emission of an α-factor analog labeled with NBD at a position
that corresponds to His3 of the normal pheromone. This analog binds
the α-factor receptor with somewhat lower afﬁnity than the Lys7
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screen, none of the recoveredmutations signiﬁcantly altered the afﬁnity
of the receptor for α-factor [100].
Based on ﬂuorescent analyses, interactions between theα-factor re-
ceptor and ﬂuorescent antagonists were found to differ drastically from
those involving the agonist [100]. The characterized antagonists for the
α-factor receptor are peptides that differ from the normal agonist,
α-factor, in that they contain truncations or alterations in the ﬁrst few
amino-terminal amino acids. They can be labeled with the ﬂuorophore
NBD at a position corresponding to Lys7 of α-factor, the same site
used to label thenormal agonist.Whenbound to normalα-factor recep-
tors, these labeled antagonists exhibit emission spectra that are signiﬁ-
cantly red-shifted compared to the spectra of receptor-bound NBD-
labeled α-factor, indicating that the labeled moiety of the antagonist
resides in a more polar environment than is the case for similarly la-
beled agonist. A mutational screen similar to that conducted for labeled
agonist was performed for the labeled antagonist [DTyr3,Lys7(NBD),
Nle12]α-factor. Surprisingly, the mutations recovered from this screen
turned out to be completely different from those found in the screen
using the labeled agonist in the following respects: 1) They resulted in
blue-shifting of the emission spectrum, indicating that they make the
environment of the ligand-attached ﬂuorophore more hydrophobic.
2) They occurred at positions with diverse predicted topologies in the
receptor, suggesting that the observed changes in emission spectrum
were not the result of changes in residues in direct contact with ligand.
3) All the mutated variant receptors recovered in the antagonist screen
were capable of initiating signaling responses upon binding ligands that
act as antagonist toward normal α-factor receptors and most of them
resulted in enhanced constitutive signaling. 4) Most of the recovered
mutations resulted in enhanced binding afﬁnity for ligands that act as
antagonists for normal receptors. The changes in ﬂuorescence emission
of ligand bound to thesemutant receptors, together with the changes in
binding afﬁnity and signaling function, indicate that the mutations re-
covered from the antagonist-based screen cause a global switch in the
receptor conformation toward a state that is easier to activate. This al-
tered receptor conformation also leads to decreased solvent accessibili-
ty of ligands that act as antagonists toward normal receptors. These
results are consistent with a model in which interactions of the
C-terminal portions ofα factor-related peptideswith one set of surfaces
on the receptor are responsible for the overall high binding afﬁnity for
receptor, whereas interactions of the N-terminal regions of these pep-
tides with a second set of surfaces on the receptor mediate activation
of signaling responses [100].
2.4. Use of ﬂuorescent ligands to monitor the kinetics of ligand binding to
GPCRs
Measurement of the kinetics of ligand interactions with GPCRs and
comparison of these kinetics with the time scales of ligand-dependent
conformational changes in receptors and of receptor interactions with
downstream components such as G proteins, kinases, and arrestins are
of great importance for understanding receptor function. The ability to
monitor the progress of receptor–GPCR interactions in real time has
been recognized as an important capability of ﬂuorescent approaches
since the early applications of ﬂuorescent ligands [53,54] and extends
today into the possibility of measuring the protein–ligand interactions
at the single molecule level on very short time scales. A signiﬁcant
advantage of ﬂuorescent approaches for measuring binding kinetics is
the capability for following the progress of a binding reaction in homo-
geneous solutions without the need to separate free ligand from bound
and perform time-consuming washing steps. Kinetic measurements
may be conducted by monitoring time-dependent changes in ﬂuores-
cence emission, such as changes in quantum yield or emission wave-
lengths, or by using microscopy or ﬂow cytometry to simply quantitate
the amount of ﬂuorescent ligand associated with cells as a function of
time. The time stamp function provided by most ﬂow cytometersmakes it possible to readily display time-dependentﬂuorescence changes
in a population of cells. For situations where it is necessary to measure
ﬂuorescence changes at time scales shorter than what can be conducted
in conventional ﬂuorimeters, microscopes, or ﬂow cytometers, ﬂuores-
cence can be measured in stop-ﬂow instruments or by using specially
designed rapid mixing ﬂow cytometers [141–144].
In an early study using ﬂow cytometry to monitor the kinetics of
binding of ﬂuorescein-labeled formyl peptide to chemotactic receptors
on human neutrophils, Sklar et al. [54] were able to recapitulate previ-
ously reported experiments that measured binding kinetics using
radiolabeled ligand. They determined a single bimolecular association
rate of 108–109 M−1 min−1, consistent with binding via a diffusion
controlled reaction to a site with partially restricted accessibility. They
also measured dissociation rates, ﬁnding that multiple processes with
different rate constants were required to ﬁt the data. This may reﬂect
a multiplicity of fates for ligand-bound receptors, including internaliza-
tion and sequestration into specialized regions of membrane.
More complex kinetics of association between GPCRs and ligands
have been observed in a number of cases. Based on FRETmeasurements,
the time-dependence of binding of Texas Red-labeled neurokinin A, an
agonist for the neurokinin NK2 receptor, to EGFP-tagged receptors can
be described by two kinetic components, a rapid rate that depends on
the concentration of ligand (2 × 106 M−1 s−1) and a slower rate
(~0.05 s−1) that was not linearly dependent on ligand concentration
[110]. The data could be ﬁt by assuming that association proceeds via
an initial bimolecular association that is followed by an isomerization
of the complex. The time course of the rapid binding step correlated
well with that of the calcium response triggered by the receptor, where-
as cyclic AMP (cAMP) responses correlated better with the slower step.
Thus, the initial binding eventmay result in transition of the receptor to
an activated state for calcium signaling followed by a slower conversion
to the activated state for cAMP signaling. A naturalN terminally-truncated
variant of neurokinin A that elicits only the calcium response exhibited
only the rapidphase of binding, suggesting that interaction of the receptor
with the N-terminal region is responsible for the slower cAMP response.
These approaches were subsequently extended to the analysis of addi-
tional ligands and mutant NK2 receptors [109].
A two-stage mechanism has also been used to describe the kinetics
of association of tetramethyl rhodamine-labeled parathyroid hormone
(PTH) with GFP-tagged PTH receptor [108]. As was observed for the
neurokinin receptor, binding could be described by a fast phase that
depended linearly on the concentration of ligand (apparent rate con-
stant of ~106 M−1 s−1) and a concentration-independent slower
phase (rate constant ~1 s−1) that could bemodeled as an isomerization
following binding. Competition with a truncated PTH derivative known
to bind only to the transmembrane regions or loops of the PTH receptor,
but not to its large extracellular N-terminal region, resulted in elimina-
tion of the slower phase of PTH binding. The time course of receptor ac-
tivation, monitored via a ﬂuorescent assay for cAMP production and via
FRET changes in a doubly-labeled PTH receptor [145], corresponded to
the slower phase of the changes in receptor–ligand FRET. This led to
the interpretation that the rapid phase of binding represents an interac-
tion of the full-length agonistwith theN-terminal domain of the receptor,
which is then followed by a conformational rearrangement to a signaling-
competent state involving interaction of ligandswith the transmembrane
region of the receptor.
The kinetics of binding of the yeast mating pheromone α-factor to
the α-factor receptor could also be conveniently studied using α-
factor peptide tagged with the environmentally sensitive ﬂuorophore
NBD, ([K7(NBD),Nle12] α-factor). Global kinetic analysis of binding ki-
netics at different concentrations could not be effectively ﬁt by a reac-
tion scheme based on a single bimolecular association but, instead,
was consistent with a sequential pathway involving an initial associa-
tion with receptor, followed by a rearrangement or redistribution of
the bound ligand. Independent support for the existence of two steps
in the association kinetics came from examination of changes in the
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time during binding, based on detection of differential changes in differ-
ent wavelength channels of the ﬂow cytometer. Although the NBD
ﬂuorophore attached to α-factor undergoes a large overall blue-shift
over the course of binding to receptors, this change actually takes
place in two phases, an initial large blue shift followed by a smaller
shift back toward longer wavelengths. Taken together, these results
suggest that α-factor initially binds to its receptor in a hydrophobic
environment, but that during a subsequent rearrangement it shifts so
as to move the tagged lysine side chain to an environment with in-
creased accessibility to solvent [82].
3. Fluorescence-based approaches for detecting ligand-dependent
conformational changes in GPCRs
3.1. Spectroscopic approaches for detection of changes in the environment
of labeled sites in receptors
Ligand binding to a G-protein coupled receptor must be associated
with conformational changes in the receptor that result in activation
of downstream signaling. However, the nature of such changes, the
mode of their coupling to ligand binding, and the mechanisms by
which they result in altered interactionswith G proteins or arrestins re-
main unclear. There is a growing body of evidence from biophysical
studies indicating that GPCRs may be capable of adopting many more
than the two (active and inactive) states that served as the basis for
early models [26,27]. In addition, there are numerous examples of sys-
tems in which different activated states of GPCRs resulting from the
binding of different ligands lead to biased agonism, the differential acti-
vation of distinct downstream signaling pathways [146].
Diverse biophysical, biochemical, and molecular biological ap-
proaches have been applied to understanding ligand-induced confor-
mational changes in GPCRs [25,147,148]. The recent determination of
the X-ray structure of the β2-adrenergic receptor in complex with a
heterotrimeric G protein has been particularly informative in this regard
[149]. However, among the biophysical approaches, ﬂuorescence-based
assays of conformational change have some signiﬁcant advantages.
1) The high time-resolution of ﬂuorescence measurements makes it
possible to follow, in real time, transitions from one state to another,
where the static states are deﬁned by X-ray crystallography. 2) The sen-
sitivity of ﬂuorescence measurements allows monitoring of conforma-
tional changes in single molecules and small numbers of molecules,
allowing analysis of conformational trajectories at a level of detail that
is not possible with large numbers of molecules in bulk solution exper-
iments. 3) Fluorescence approaches allow probing of particular regions
of receptor structure into which ﬂuorescent reporters are introduced.
4) Some ﬂuorescent labeling approaches allow examination of recep-
tors in their native environments in cells or membranes.
Detection of changes in the ﬂuorescence emission of intrinsic or
introduced ﬂuorophores at different positions in GPCRs has provided
important information about the nature of conformational changes in
receptors (see Fig. 3). Despite the fact that intrinsic tryptophan absor-
bance spectroscopy provided initial evidence for conformational change
upon activation of rhodopsin [150], only a fewmeasurements of the in-
trinsic tryptophanﬂuorescence of GPCRshave been conducted, presum-
ably because of the complexity of the spectra in proteins containing
multiple tryptophan residues. Tryptophan emission changes in the leu-
kotriene B4 receptor [151], the metabotropic glutamate receptor
subtype 1 [152], and the thromboxane A2 receptor [153] have all pro-
vided indications of ligand-speciﬁc conformational changes.
Multiple labeling strategies have been used to introduce ﬂuores-
cent reporters at different sites in GPCRs. One of the ﬁrst studies of
this kind, conducted by Kobilka and co-workers, introduced
the small, membrane-permeable, environmentally-sensitive probe,
IANBD (N,N′-dimethyl-N-(iodoacetyl)-N′-(7-nitrobenz-2 -oxa-1,3-
diazol-4 -yl)ethylenediamine) for labeling of cysteine residues inthe β2-adrenergic receptor [154]. Puriﬁed IANBD-labeled β2-
adrenergic receptors exhibited a decrease in ﬂuorescence intensity
in response to agonist binding that was reversed by addition of an-
tagonist. A remarkable linear correlation was observed between
the magnitude of the decrease and the efﬁcacy of the different li-
gands, consistent with the hypothesis that the change in ﬂuores-
cence reﬂected conformational changes associated with receptor
activation. In agreement with this hypothesis, this group also
showed that inverse agonists produced small, but reproducible, in-
crease in IANBD ﬂuorescence. A subsequent study [155] localized
the relevant IANBD labeling sites in the receptor to Cys125 and
Cys285, in the third and sixth transmembrane segments, respective-
ly, implicating these two helical segments in ligand-dependent con-
formational changes in agreement with contemporaneous results
from electron paramagnetic resonance data [156].
The Kobilka group was also able to achieve site-speciﬁc attachment
of labels to Cys265 in the third intracellular loop of puriﬁed β2-
adrenergic receptors by reacting with either ﬂuorescein maleimide or
tetramethylrhodamine-maleimide (TMR) [157–159]. Binding of ago-
nists to the receptor labeled with ﬂuorescein at this position resulted
in a decrease in ﬂuorescence emission and in susceptibility to iodide
quenching, consistent with the ligand-dependent motion of this loop,
which is near the site of interaction with the G protein [158]. Receptors
labeled with ﬂuorescein at Cys265 were also studied using ﬂuorescence
lifetime measurements, to assay conformational heterogeneity of the
protein [157]. Measurement of the lifetimes associated with decay of
ﬂuorescent excited states provides much of the same information that
can be obtained from steady state measurements of emission, but ﬁtting
these decays to multiple exponential functions introduces the important
additional capacity for distinguishing properties of different subpopula-
tions in samples where not all molecules are behaving identically.
Fluorescein attached to unliganded receptor exhibited a single broad
distribution of ﬂuorescent lifetimes, indicative of a single, but ﬂexible,
conformational state. This distribution narrowed in the presence of an-
tagonist, suggesting that antagonist binding causes a reduction in ﬂexi-
bility. Binding of the full agonist isoproterenol led to the appearance of
an additional class of short ﬂuorescence lifetimes mixed in with a
population of ﬂuorescence decays with lifetimes similar to those of
unliganded receptor. These results led to the important idea that,
while agonist bindingmay lead to the appearance of a distinct activated
state of receptors, at any given time, not all ligand-bound receptors
adopt this state. Fluorescence lifetime experiments were also used to
show that the states resulting from binding of partial agonists to the
β2-adrenergic receptor were different from the states induced by bind-
ing of the full agonist, implying that different types of agonists may
cause receptors to adopt a diversity of receptor conformations not
restricted to simple inactive and active states, perhaps providing a
structural basis for biased agonism.
Fluorescence-based approaches were also used to speciﬁcally detect
conformational changes around proposed “ionic lock” interactions be-
tween the third and sixth transmembrane segments of GPCRs [160].
Starting with a variant β2-adrenergic receptor from which all reactive
cysteine residues had been removed, a cysteine was introduced in
place of Ala271 in the sixth transmembrane segment and a tryptophan
was substituted for Ile135 in the third transmembrane segment. This
allowed the speciﬁc introduction of a ﬂuorescent bimane group at posi-
tion 271 that could be quenched if, as seen in crystal structures, disrup-
tion of the ionic lock results in alteration of a helical twist in the sixth
transmembrane, bringing the bimane into close proximity to the intro-
duced tryptophan at position 135. Minimal quenching was observed in
the absence of antagonist, but binding of different agonists led to reduc-
tions in bimane emission that could be correlated with the particular li-
gand structures. Ligand-dependent changes in ﬂuorescence of a bimane
group attached to Cys265 were also used to demonstrate retention of
native-like responses to ligands by a modiﬁed β2-adrenergic receptor
used for X-ray structure determination [23].
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upon binding to different ligands were analyzed by Kobilka and co-
workers using β2-adrenergic receptors labeled with TMR at Cys265. This
allowed the development of a detailedmodel inwhich sequential interac-
tions of different chemical groups on ligands lead to different stages of re-
ceptor activation and internalization [161,162]. A disadvantage of the use
of ﬂuorescent reporters attached to puriﬁed receptors is the relatively
slow rates of change of ﬂuorescence emission (comparedwith physiolog-
ical responses and changes detected by FRET) upon addition of ligands.
This ismost likely the result of solubilization and puriﬁcation of receptors,
and of conducting the analysis in detergent micelles in the absence of
other cell components [160,163].
Covalently attached environmentally sensitive ﬂuorescent reporters
have also been used to monitor conformational changes in GPCRs other
than the β2-adrenergic receptor. Bimane groups attached to cysteine
residues introduced into rhodopsin at different positions were used to
monitor conformational changes upon light-dependent conversion to
the Meta II state [164]. Quenching of similarly introduced bimane
groups resulting from proximity to tryptophan residues in peptide ana-
logs of the C-terminal of the G protein transducin was used to map the
geometry of the rhodopsin–transducin interaction [165]. The mobility
of ﬂuorescent probes attached to rhodopsin was analyzed in different
states of activation using time resolved anisotropy measurements
[166]. Bimanes introduced at speciﬁc positions in the ghrelin receptor
reconstituted into lipid nanodisks exhibited ligand-dependent changes
in steady state emission and lifetime distributions [167]. In addition,
changes in emission from this labeled receptor were observed upon
the addition of G proteins and arrestin, providing evidence for a com-
plex landscape of ligand- and effector-induced conformational states.
Bimane labeling has also been used to study the effects of an allosteric
ligand of the cannabinoid CB1 receptor, providing evidence that the li-
gand stabilizes an agonist-bound state of the receptor that is, surprising-
ly, not capable of efﬁcient G protein activation [163].
3.2. Studies of ligand-dependent conformational changes in GPCR studies
using intramolecular FRET
Changes in emission of a single ﬂuorescent label, while providing
information about changes in the environment of the speciﬁc reporter
group, can be difﬁcult to interpret in terms of actual structural changes
in receptors. Furthermore, most studies involving conjugation of small
environmentally-sensitive ﬂuorophores to receptors require prior solu-
bilization and puriﬁcation of receptors, removing them from their na-
tive environments. FRET-based approaches make it possible to detect
changes in distances between ﬂuorescent groups at speciﬁc locations
in receptors in the presence and absence of different ligands (see
[168]). When FRET is measured between different ﬂuorescent proteins
fused to receptors, distance changes can be detectedwhile the receptors
are present in themembranes of living cells. A signiﬁcant concern is the
problem of distinguishing intramolecular FRET from intermolecular
FRET, since FRET-based approaches are also commonly used to study
the nearly ubiquitous oligomerization of GPCRs. In a number of cases,
the absence of intermolecular contributions to FRET has been demon-
strated by the absence of FRET observed when molecules that are sepa-
rately singly labeled at the two relevant positions are mixed together or
co-expressed [145,169].
Although it is convenient to conduct FRET using genetically encoded
ﬂuorescent proteins, such proteins have disadvantages compared to
small ﬂuorophores: 1) They are large, sometimes of greater mass than
the proteins towhich they are fused. This can lead to alterations in local-
ization, stability, or functional properties of the proteins being studied.
For example, in some cases, introduction of large ﬂuorescent proteins
[170], and even small tagging sequences [171] in the third intracellular
loop of a receptor can interfere with activation of G proteins by recep-
tors. The overall size of ﬂuorescent proteins makes it difﬁcult to obtain
distance information for groups that are expected to be in closeproximity. 2) The actual locations of the exciting and emitting dipoles
in ﬂuorescent proteins are not well-deﬁned, and ﬂuorophores are gen-
erally attached to proteins via ﬂexible linkages, making it difﬁcult to in-
terpret FRET efﬁciencies in terms of structurally relevant distances. 3)
Fluorescent protein tags can be subject to proteolytic cleavage separat-
ing them from the proteins to which they are supposed to be attached
[172]. Thus it is important to check that FRET signals are not being
interpreted based on cleaved ﬂuorescent proteins with irrelevant loca-
tions. 4) Fluorescent proteins do not have optimal photochemical and
photophysical behaviors. They are not as bright or photostable as some
commonly used small molecule ﬂuorophores, making them, for example,
generally unsuitable for single molecule studies.
To avoid some of the problems with the use of ﬂuorescent proteins,
various approaches have been used for incorporating genetically
encoded sequences that allow attachment of small ﬂuorophores at spe-
ciﬁc positions to GPCRs without the need for puriﬁcation of receptors.
One of the most commonly used approaches is the use of small mem-
brane permeant arsenical compounds, known as FlAsH reagents [173],
that bindwith high afﬁnity to sequences with a particular conﬁguration
of four cysteine residues. Reﬁnements in labeling conditions and accep-
tor sequences have rendered these reagents fairly speciﬁc for target se-
quences, with minimal background and toxicity to cells (see [169]).
Other, less frequently used approaches for introducing small molecule
labels at deﬁned positions in receptors include the use of ﬂuorophore-
conjugatedmetal chelating compounds expected to bind to histidine re-
peats [174], enzyme tags that catalyze self-labeling reactions [175], and
short sequences that can be recognized by exogenous enzymes as ac-
ceptors for labeling reactions (see [176]). However, the metal chelating
compounds are relatively low afﬁnity reagents that bind reversibly and
the enzyme tags result in fusion proteins that are almost as massive as
the ﬂuorescent proteins. To date, the potential usefulness of short en-
zyme target sequences for labeling GPCRs does not seem to have been
fully exploited.
FRET-based approaches have been applied by several groups to
detecting conformational changes in β-adrenergic receptors. Initial
studies used puriﬁed protein with a FlAsH reagent in the C-terminal
tail and an Alexa Fluor 568 covalently attached to Cys265 (see above)
[177]. The distance from the C-terminal to the third intracellular loop,
calculated based on FRET efﬁciency was ~60 Å, indicating that the tail
may adopt an extended conformation. All tested ligands produced an
increase in FRET efﬁciency when the FlAsH reagent was positioned at
the proximal end of the C-terminal tail. Results were less consistent
when the FlAsH was at the extreme distal end of the tail. Different
changes in FRET efﬁciency of labels at different sites in the C-terminal
region were detected based on different types of ligand bound to the
receptors. FRET between a FlAsH label in the third intracellular loop of
β2-adrenergic receptors and cyan ﬂuorescent protein fused at the
C-terminal has also been detected in living cells [178]. This study also
detected an increase in FRET upon binding of ligand. The fact that the
time scale of the increase was shorter than that of ﬂuorescence changes
that have been reported for studies with puriﬁed detergent-solubilized
β2-adrenergic receptors suggests that the particular structure of the sur-
rounding amphiphilic molecules can signiﬁcantly affect receptor con-
formational transitions, a conclusion that is also supported by NMR
studies of β2 in different detergents [179]. A subsequent study exam-
ined FRET between cyan ﬂuorescent protein fused at the third intracel-
lular loop of the β2-adrenergic receptor and yellow ﬂuorescent protein
inserted into the C-terminal tail. As found in other studies, differences
in the FRET efﬁciencies and the kinetics of FRET changes indicated that
the receptor can adopt a range of conformations, consistent with the
idea of biased agonism [180].
Theα2A-adrenergic receptor has also been the target of a number of
analyses using intramolecular FRET. In initial studies of receptors con-
taining combinations of CFP and YFP inserted into the third intracellular
loop and at the C-terminal tail of receptors expressed in live cells, a
decrease in FRET was detected upon addition of agonist [145,181].
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Fig. 3. Schematic diagram of four types of ﬂuorescent experiments used to examine ligand–receptor interactions and ligand-dependent conformational changes in G protein coupled
receptors. Fluorophores used as reporters are shown as colored disks. A) Use of a ﬂuorescently tagged ligand with an untagged receptor for measuring ligand binding, determination of
the environment of the bound ligand, and the kinetics of ligand binding. The ligand is represented as a black crescent. B) Use of intermolecular ligand–receptor Fluorescence Resonance
Energy Transfer (FRET) to measure ligand binding, map the geometry of ligand–receptor interactions, and measure the kinetics of ligand binding. C) Use of a single ﬂuorescent label
attached to receptor (most often at the cytoplasmic end of the sixth transmembrane helix) to measure changes in conformation induced by ligand binding. D) Use of intramolecular
FRET between two labels on a receptor (most often the cytoplasmic end of the sixth transmembrane helix and the C-terminal tail of the receptor) to measure distance changes induced
by ligand binding. Note that, for simplicity, receptors are shown asmonomers, despite a large body of evidence that they exist as oligomers inmembranes. Also, the ﬁgure is not drawn to
scale and does not reﬂect that ﬂuorophores consisting of ﬂuorescent proteins can be of approximately the same size as the entire receptor.
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more rapid than had been observed with previous studies of conforma-
tional change in puriﬁed detergent solubilized receptors [145]. Binding
of inverse agonist results in a FRET change that is opposite to that in-
duced by agonist binding [182]. Similar conformational changes in the
α2A-adrenergic receptor, as well as a correlation between agonist efﬁca-
cy and the half-time of receptor activation were detected using con-
structs containing FlAsH bound to the third intracellular loop and CFP
fused at the C-terminal [183]. The short time resolution of the system
was also exploited in order to measure the dependence of the kinetic
parameters of the receptor response on ligand concentration, providing
a view of the pharmacology of the system that may bemore relevant to
what happens in cells than typical long-term assays where the compo-
nents are all allowed to reach an equilibrium state. The change in recep-
tor conformation reported by FRET changes occurred on a faster time
scale than activation of G protein, assayed using a separate FRET report-
er system [184].
Intramolecular FRET has also been used to monitor activation of
muscarinic acetylcholine receptors. An M2 receptor construct with a
FlAsH tag in the third intracellular loop and CFP at the C-terminus,
expressed in HEK cells, exhibited a decrease in FRET in response to the
agonists acetylcholine and carbachol, though at levels of agonist thatwere higher than are typically required to elicit responses in other as-
says [185]. Allosteric negative modulators of signaling, tested by them-
selves, had little or no effect on FRET, but inhibited the responses of
orthosteric agonists. Similar FRET reporter systems based on FlAsH
and CFP have been constructed for M1, M3, and M5 muscarinic acetyl-
choline receptors and a reporter based on CFP and YFP has been used
to study the M1 receptor [170,171,186,187]. Each of these exhibits de-
creased FRET upon binding to agonists. A FRET construct based on the
M3 receptor was used to examine the kinetics of activation and deacti-
vation of a constitutively activeM3 variant. Themutation's effects could
be explained by a decrease in the rate of deactivation rate better than by
an increase in activation rate, a conclusion that would be difﬁcult to
draw without the time resolution that is possible with FRET measure-
ments [188].
Among other receptors studied by intramolecular FRET, the parathy-
roid hormone receptor stands out for its slowkinetics of activation (~1 s
time constant, compared with b40 ms for the α2A-adrenergic receptor
measured in parallel) [145]. Conformational changes have also been de-
tected based on FRET changes in the A2a-adenosine receptor [169] and
the bradykinin B2 receptors [189]. FRET measurements have also been
used as evidence for changes in the conformation of the bradykinin re-
ceptor in response to ﬂuid shear stress.
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Major technological advances allowing detection and ﬂuorescence-
based imaging of single molecules have, to date, had relatively little im-
pact on understanding mechanisms of ligand dependent signaling by
GPCRs, although such approaches have found important applications
in characterizing the oligomeric states of receptors and their dynamics
in cell membranes [190–194]. A commonly used approach for single
molecule ﬂuorescence is to tether themolecule of interest to a solid sur-
face in order to keep it in the ﬁeld of view for the longest possible time.
Such tethering has been reported for single CCR5 chemokine receptors
[195]. However, it is not clear to what extent tethering could affect the
dynamics of receptors being studied (see [196]). Analysis of photon
bursts from freely diffusing single solubilized β2-adrenergic receptors
speciﬁcally labeled with ﬂuorescein at Cys265 led to the conclusion that
the attached ﬂuorophore experiences more than one environment, even
under native, unliganded conditions. Binding of the agonist isoproterenol
signiﬁcantly reduced the burst size (equivalent to a reduction in emission
in bulk experiments), while retaining heterogeneity of burst sizes, indica-
tive of heterogeneity of environments of the label. Such heterogeneity
could be the result of rapid binding and unbinding of ligand [197]. A sub-
sequent study overcame limitations on the length of time over which it is
possible to observe freely diffusingmolecules through the use of an “Anti-
Brownian ELectrokinetic” (ABEL) trap to retain individual β2-adrenergic
receptors labeled at Cys265 with tetramethylrhodamine in the ﬁeld of
view for up to many hundreds of milliseconds. This approach allowed
monitoring of the intensities and lifetimes of ﬂuorescence emission of in-
dividualmolecules for long enough to obtainwell-deﬁnedmeasurements
and even observe discrete transitions of individual receptors between dif-
ferent states. The transitions occurred over time scales ranging frommil-
liseconds to seconds. A 2D “map” of intensity and lifetime generated from
the singlemolecule data showed differences in the occupancy of different
intensity and lifetime states between the ligand-free receptor and
agonist-bound receptor. However, both appeared to sample awide varie-
ty of different environments [198].
5. Outlook
The contributions made by ﬂuorescence-based approaches for
studying ligand-dependent signaling by GPCRs are likely to continue.
It is to be hoped that a greater proportion of the wide variety of ﬂuores-
cent ligands reported in literature will become available commercially,
or by inter-laboratory exchange. These ligandswill continue to be useful
for high-throughput screening for newGPCR ligands, for understanding
themechanisms underlying the relationship between the binding of dif-
ferent ligands and receptor activation, for the development of thermo-
stable receptors for structural studies, and as a replacement for
radioligands in routine binding assays. It can also be anticipated that
the application of new and improved technologies to ﬂuorescent re-
porters and FRET pairs coupled to receptor proteins will be valuable in
extrapolating from the rapidly growingwealth of structural information
about GPCRs to an understanding of the mechanisms and dynamic as-
pects of receptor signaling and regulation. Technologies that are likely
to be critical for progress in this area include: 1) improved tagging proce-
dures for speciﬁcally introducing small ﬂuorophores at speciﬁc positions
in receptors in living cells; 2) improved approaches for immobilizing
and trapping receptors for single molecule spectroscopy; 3) introduction
of new technologies that could greatly enhance detection ofweakﬂuores-
cence emission, such as enhancement by metals [199] and optical anten-
nas [200]; 4) procedures for simultaneously collecting and integrating
intensity, anisotropy, and lifetime data in single molecule experiments;
5) continuing optimization of the ﬂuorescent, biochemical, and pharma-
cological properties ofﬂuorescent ligands for particular receptors; 6) inte-
gration of ﬂuorescence spectroscopy with newly-developed technologies
for super-resolution imaging [201]; and 7) application of quantumdots to
molecular spectroscopy for understanding receptor function. Althoughthey provide bright ﬂuorescent sources with useful spectral properties,
the relatively large dimensions of quantum have prevented them from
being useful as environmental probes of particular regions of proteins
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